Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 6, 2025 • 5:01 PM ET

Date/Time Source News Release
06/02/2025 08:30 AM EDT Business Wire Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
05/28/2025 08:30 AM EDT Business Wire Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
05/23/2025 08:30 AM EDT Business Wire Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
04/17/2025 08:30 AM EDT Business Wire Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
03/19/2025 08:30 AM EDT Business Wire Vistagen to Present at the 2025 Anxiety and Depression Association Conference
03/04/2025 08:30 AM EST Business Wire Vistagen to Participate in Stifel 2025 Virtual CNS Forum
02/20/2025 08:30 AM EST Business Wire Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
02/13/2025 04:30 PM EST Business Wire Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
02/06/2025 08:30 AM EST Business Wire Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
02/05/2025 08:30 AM EST Business Wire Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Page

Additional News

As of June 6, 2025 • 5:01 PM ET

Date/Time Source News Release
05/19/2025 12:02 PM EDT ABN Newswire Ellis Martin Report: Vistagen Therapeutics Inc. (VTGN) CEO Shawn Singh - A Revolutionary Fast Acting Nasal Spray Targeting Social Anxiety Disorder
05/15/2025 09:15 AM EDT Zacks Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
05/14/2025 05:35 PM EDT Zacks Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
05/13/2025 05:15 PM EDT Zacks Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
05/12/2025 05:10 PM EDT Zacks Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
02/14/2025 06:19 PM EST SeekingAlpha Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
02/13/2025 08:55 PM EST SeekingAlpha Vistagen advances Phase 3 SAD trials with 2025 data readout target
02/13/2025 08:47 PM EST SeekingAlpha Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
02/13/2025 05:55 PM EST Zacks VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
02/13/2025 04:33 PM EST SeekingAlpha VistaGen Therapeutics GAAP EPS of -$0.46 beats by $0.05, revenue of $0.23M beats by $0.05M
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.